ArticleBioinformation2026
Exploring molecular pathways in Alzheimer's disease neurodegeneration using biomarkers.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need to better understand the role of tumor necrosis factor-alpha (TNF-α) in Alzheimer's disease (AD) and its relationship with brain atrophy and cognitive decline is highly relevant. Therefore, it is of interest to investigate the role of tumor necrosis factor-alpha (TNF-α) in Alzheimer's disease (AD) by analyzing its relationship with brain atrophy and cognitive decline in 80 AD patients. Our results show a significant correlation between increased CSF TNF-α levels and hippocampal atrophy. Additionally, TNF-α level were associated with other clinical variables, emphasizing its role in neuroinflammation. Thus, TNF-α as a potential biomarker for Alzheimer's disease progression. Further research is needed to assess its therapeutic potential. The advancement to knowledge in this study is the identification of a significant correlation between elevated TNF-α levels and hippocampal atrophy in Alzheimer's disease, supporting TNF-α as a potential biomarker for disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.